Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease

Heart and Vessels

Volumn 27, Issue 4, 2012, Pages 337-343

  Takahashi, Yuji ^a   Satoh, Mamoru ^a   Tabuchi, Tsuyoshi ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Angina pectoris; Atherosclerosis; Percutaneous coronary intervention; Statin

Indexed keywords

ANGIOPOIETIN 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEPTIN; NITRIC ACID DERIVATIVE; PRAVASTATIN; SCATTER FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOPOIETIN 2 BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LEPTIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCATTER FACTOR BLOOD LEVEL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; VASCULOTROPIN BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; ANGIOGENIC PROTEINS; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DOWN-REGULATION; FEMALE; HEPATOCYTE GROWTH FACTOR; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; LEPTIN; LIPIDS; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; PYRROLES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864241291     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-011-0156-y     Document Type: Article

References (29)

1. Woods AJ, Stock MJ (1996) Leptin activation in hypothalamus. Nature 381:745
2. Beltowski J (2006) Leptin and atherosclerosis. Atherosclerosis 189:47-60 (Pubitemid 44441296)
3. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR (1998) Biological action of leptin as an angiogenic factor. Science 281:1683-1686 (Pubitemid 28435586)
4. La Cava A, Matarese G (2004) The weight of leptin in immunity. Nat Rev Immunol 4:371-379 (Pubitemid 38649279)
5. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N (2001) Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104:3052-3056 (Pubitemid 34014056)
6. Lee KW, Lip GYH, Blann AD (2004) Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110:2355-2360 (Pubitemid 39407339)
7. Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, Ishikawa T, Kohri K, Suehiro A, Kakishita E, Namba M (2003) Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with type 2 diabetes. Diabet Med 23:617-622 (Pubitemid 43830061)
8. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071-1080 (Pubitemid 38541684)
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504 (Pubitemid 38477774)
10. Nissen SE (2005) Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) trial. Am J Cardiol 96:61F-68F (Pubitemid 41207735)
11. Djoba Siawaya JF, Roberts T, Babb C, Black G, Golakai HJ, Stanley K, Bapela NB, Hoal E, Parida S, van Helden P, Walzl G (2008) An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS ONE 3:e2535
12. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
13. Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K, Olsson T (1999) Leptin is associated with increased risk of myocardial infarction. J Intern Med 246:409-418 (Pubitemid 29479923)
14. Wallerstedt SM, Eriksson AL, Nikiason A, Ohisson C, Hedner T (2004) Serum leptin and myocardial infarction in hypertension. Blood Press 13:243-246 (Pubitemid 39248188)
15. Singhal A, Farooqi SI, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, Lucas A, Deanfield J (2002) Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 106:1919-1924 (Pubitemid 35176295)
16. Peelman F, Waelput W, Iserentant H, Lavens D, Eyckerman S, Zabeau L, Tavernier J (2004) Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog Lipid Res 43:283-301 (Pubitemid 38952616)
17. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HY (2001) Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33:95-102 (Pubitemid 32655888)
18. Cao R, Brakenhieim E, Wahlestedt C, Thyberg J, Cao Y (2001) Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 98:6390-6395 (Pubitemid 32488247)
19. Bouloumie A, Marumo T, Lafontan M, Busse R (1999) Leptin induces oxidative stress in human endothelial cells. FASEB J 13:1231-1238 (Pubitemid 29300368)
20. Mavri A, Poredoš P, Suran D, Gaborit B, Juhan-Vague I, Poredoš P (2011) Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting. Heart Vessels 26:31-38
21. Chiba T, Shinozaki S, Nakazawa T, Kawakami A, Ai M, Kaneko E, Kitagawa M, Kondo K, Chait A, Shimokado K (2008) Leptin deficiency suppresses progression of atherosclerosis in apoEdeficient mice. Atherosclerosis 196:68-75
22. Cao Y (2007) Angiogenesis modulates adipogenesis and obesity. J Clin Invest 117:2362-2368 (Pubitemid 47494333)
23. Davignon J (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (Suppl 1):III39-43 (Pubitemid 38786442)
24. Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S (2008) Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessel 23:249-256
25. Zhao SP, Wu ZH (2005) Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta 360:133-140
26. von Eynatten M, Schneider JG, Hadziselimovic S, Hamman A, Bierhaus A, Nawroth P, Dugi KA (2005) Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 28:754-755 (Pubitemid 40315347)
27. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, Berger PB, Somers VK (2004) Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109:2181-2185 (Pubitemid 38625394)
28. Söderberg S, Colquhoun D, Keech A, Yallop J, Barnes EH, Pollicino C, Simes J, Tonkin AM, Nestel P, Study Investigators LIPID (2008) Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) 33:123-130
29. Strandberg TE, Vanhangen H, Tikkanen MJ (1999) Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 353:118-119 (Pubitemid 29088085)